1 N-gamma into a mouse model of an established metastatic brain tumor.

2 iously irradiated patients with recurrent or metastatic brain tumors.

3 ntially enhance the management of primary or metastatic brain tumors.

4 hift in the use of natural product drugs for metastatic brain tumors.

5 uld be based on the histologic origin of the metastatic brain tumor and not on the lipophilicity of t

6 s, which are rarely used in the treatment of metastatic brain tumors because they are thought to not

7 ly used, effective treatment for primary and metastatic brain tumors, but it also produces radiation-

8 eased tissue concentrations of paclitaxel in metastatic brain tumors compared with gliomas, support t

9 e the differentiation of solitary intraaxial metastatic brain tumors from gliomas.

10                       Our hypothesis is that metastatic brain tumors from tumors with intrinsically l

11   Xenograft mouse models of glioblastoma and metastatic brain tumors (from lung and breast cancer) we

12       However, use of local chemotherapy for metastatic brain tumors has not been defined.

13            Melanoma is the third most common metastatic brain tumor in the United States and is a maj

14 enfluridol treatment inhibited the growth of metastatic brain tumors introduced by intracardiac or in

15 er, P-gp expression in the neovasculature of metastatic brain tumors is similar to the P-gp expressio

16 fteen patients with progressive or recurrent metastatic brain tumors that failed to respond to surger

17 rradiated patients with recurrent primary or metastatic brain tumors was 100 mCi.

18 rd of care for the chemotherapy treatment of metastatic brain tumors, which has been generally limite